FDA Investigates Death of Boy Who Got Sarepta's Gene Therapy
The death occurred on June 7, according to a statement from the US Food and Drug Administration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Wall Street Reacts: Lilly's Weight-Loss Pill Falls Short--But a New Obesity Drug War Just Began
Eli Lilly's (NYSE:LLY) next big bet on obesityan experimental pill called orforglipronjust returned late-stage trial data. The results? A solid 11% average weight loss over 18 months, or roughly 25 pounds. But it wasn't enough to impress Wall Street. Investors had been hoping for Wegovy-level numbers (1415%), and Lilly came in light. Shares dropped more than 12% in premarket trading Thursday. Meanwhile, rival Novo Nordisk (NYSE:NVO), the maker of Wegovy and Rybelsus, surged over 8% in Copenhagenits best intraday jump in months. Warning! GuruFocus has detected 4 Warning Sign with UAL. Still, the bigger picture might not be so bearish. Pills like orforglipron could play a critical role in making obesity drugs more accessible, especially as the market heads toward an estimated $95 billion by 2030. Unlike injectables, orforglipron is easier to make, potentially cheaper, and has a side-effect profile in line with existing GLP-1smainly nausea, vomiting, and diarrhea. About 10% of patients dropped out, but importantly, there were no signs of liver issues, which have plagued some oral rivals. Obesity specialists say effectiveness alone won't be the only driversafe, easy-to-use options matter just as much. Lilly says it will file for approval by the end of 2025, with hopes of hitting the market shortly after. The company is already stockpiling ingredients and has parked over $600 million worth of orforglipron-related inventory. The move suggests management is betting big despite the modest headline number. On the other side, Novo is gearing up for a decision on a higher-dose version of its Rybelsus pill after working through semaglutide production constraints. If both pills make it to shelves, they could open up a new front in the obesity drug warone focused not just on efficacy, but price, convenience, and scale. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Insulet beats second-quarter profit estimates on strong demand for insulin pumps
(Reuters) -Medical device maker Insulet beat Wall Street estimates for second-quarter profit and revenue on strong demand for its wearable insulin pumps, sending its shares up nearly 10% in premarket trading on Thursday. Insulet has been benefiting from the expanded approval for its automated insulin delivery device, Omnipod, which offers a convenient alternative to conventional pumps with external tubing by eliminating the need for multiple daily injections for people with insulin-dependent diabetes. Its Omnipod 5 device was cleared for use in both type 1 and type 2 diabetes patients last year. The company now expects its annual revenue to grow in the range of 24% to 27% from a year earlier, compared with its previous projection of 19% to 22%, betting on strong demand for Omnipod 5. The results suggest "Insulet's momentum is not only continuing, but accelerating", Baird analyst Jeff Johnson said. The company projects annual Omnipod revenue growth of 25% to 28%, up from a 20% to 23% growth forecast previously. Its Omnipod devices brought in sales of $639 million in the second quarter, above analysts' estimate of $606.15 million, according to data compiled by LSEG. On an adjusted basis, the company earned $1.17 per share, beating estimates of 93 cents. Total revenue jumped 33% to $649.1 million for the quarter ended June 30, compared with estimates of $612.22 million.
Business Wire
5 minutes ago
- Business Wire
Tivic Health to Report Second Quarter 2025 Financial Results on August 14
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link About Tivic Health Systems, Inc. Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune system. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ under development for the treatment of acute radiation syndrome (ARS), has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate the pathways implicated in many prevalent and debilitating diseases. Tivic Health's first FDA approved product ClearUP™ is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors', as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
